Synapse - Department of Medicine

Search Within

Department of Medicine

Results (39667)

In vivo fluorescence confocal microscopy of skin in the transgenic green fluorescent protein mouse

Meeting Abstract

Swindle, L.; Moricz, C.; Wolchok, J.; Busam, K.; Halpern, A.
Journal of Investigative Dermatology (2003)

Correlation of prostate cancer gene expression profiles with outcome following radical prostatectomy: Can we improve upon existing prognostic models?

Meeting Abstract

Stephenson, A. J.; Satagopan, J.; Smith, A.; Kattan, M. W.; Levcovici, S. S.; Scher, H. I.; Scardino, P. T.; Reuter, V. E.; Gerald, W. L.
Proceedings of the American Association for Cancer Research Annual Meeting (2003)

Fulltext@MSK | Save

Pulsatile administration of the EGF receptor inhibitor Iressa (ZD1839) is significantly more effective than continuous dosing for sensitizing tumors to taxol

Meeting Abstract

Solit, D. B.; She, Y.; Moasser, M. M.; Hudis, C. A.; Kris, M. G.; Scher, H. I.; Rosen, N.; Sirotnak, F. M.
Proceedings of the American Association for Cancer Research Annual Meeting (2003)

Fulltext@MSK | Save

ID deficiency cooperates with ansamycins to inhibit the growth of breast tumors that develop spontaneously in MMTV-neu transgenic mice

Meeting Abstract

Solit, D. B.; De Candia, P.; Rosen, N.; Benezra, R.
Proceedings of the American Association for Cancer Research Annual Meeting (2003)

Fulltext@MSK | Save

Response and resistance to gefitinib (ZD1839, Iressa) in HER overexpressing tumor cells is mediated through the PI3K/Akt pathway

Meeting Abstract

She, Q. B.; Solit, D.; Basso, A.; Rosen, N.; Moasser, M. M.
Proceedings of the American Association for Cancer Research Annual Meeting (2003)

Fulltext@MSK | Save

Results of a phase I dose escalation study in the treatment of inoperable non-small cell lung cancer

Meeting Abstract

Rosenzweig, K. E.; Yorke, E.; Jackson, A.; Nayak, R.; Rusch, V. W.; Kris, M. G.; Fuks, Z.; Ling, C. C.; Leibel, S. A.
International Journal of Radiation Oncology, Biology, Physics (2003)

Fulltext@MSK | Save

Immunogenicity of GD2 lactone (GD2L)-KLH conjugate plus immunological adjuvant QS-21 vaccine in patients with melanoma

Meeting Abstract

Ragupathi, G.; Livingston, P. O.; Hood, C.; Krown, S. E.; Chapman, P. B.; Wolchok, J. D.; Williams, L. J.; Oldfield, R. C.; Hwu, W. J.
Proceedings of the American Association for Cancer Research Annual Meeting (2003)

Fulltext@MSK | Save

Molecular adjuvants for cancer vaccines: From bench to bedside, with a stop in the kennel

Meeting Abstract

Perales, M. A.; Bergman, P. J.; Houghton, A. N.; Wolchok, J. D.
European Cytokine Network (2003)

Fulltext@MSK | Save

The epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib (TarcevaTM, OSI-774), is an active agent in bronchioloalveolar carcinoma (BAC) and its variants: Interim results of a phase II trial

Meeting Abstract

Patel, J.; Miller, V.; Kris, M.; Shah, N.; Tyson, L.; Pizzo, B.; Zakowski, M.; Cespon, M.; Heelan, R.; Johnson, D.
EJC Supplements (2003)

Fulltext@MSK | Save

Phase II clinical experience with the novel proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent and mantle cell lymphomas

Meeting Abstract

O'Connor, O. A.; Wright, J.; Moskowitz, C.; Straus, D.; Macgregor-Cortelli, B.; Muzzy, J.; Choi, P.; Schenkein, D.; Zelenetz, A. D.
EJC Supplements (2003)

Fulltext@MSK | Save